NI201900102A - Compuestos inhibidores de ask1 y usos de los mismos - Google Patents

Compuestos inhibidores de ask1 y usos de los mismos

Info

Publication number
NI201900102A
NI201900102A NI201900102A NI201900102A NI201900102A NI 201900102 A NI201900102 A NI 201900102A NI 201900102 A NI201900102 A NI 201900102A NI 201900102 A NI201900102 A NI 201900102A NI 201900102 A NI201900102 A NI 201900102A
Authority
NI
Nicaragua
Prior art keywords
compounds
same
inhibiting compounds
ask1
methods
Prior art date
Application number
NI201900102A
Other languages
English (en)
Inventor
David Brown Samuel
Original Assignee
Seal Rock Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seal Rock Therapeutics Inc filed Critical Seal Rock Therapeutics Inc
Publication of NI201900102A publication Critical patent/NI201900102A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)

Abstract

En el presente documento se describen compuestos, que incluyen sales, solvatos, metabolitos, profármacos farmacéuticamente aceptables de los mismos, métodos para preparar tales compuestos, composiciones farmacéuticas que comprenden tales compuestos y métodos para usar dichos compuestos para tratar la esteatohepatitis no alcohólica y otras enfermedades caracterizadas por la curación disfuncional del tejido y fibrosis.
NI201900102A 2017-04-05 2019-10-03 Compuestos inhibidores de ask1 y usos de los mismos NI201900102A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762482085P 2017-04-05 2017-04-05

Publications (1)

Publication Number Publication Date
NI201900102A true NI201900102A (es) 2020-05-15

Family

ID=63712299

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201900102A NI201900102A (es) 2017-04-05 2019-10-03 Compuestos inhibidores de ask1 y usos de los mismos

Country Status (31)

Country Link
US (2) US20210087167A1 (es)
EP (1) EP3606519B1 (es)
JP (1) JP7196093B2 (es)
KR (1) KR102665145B1 (es)
CN (1) CN110730661B (es)
AR (1) AR111407A1 (es)
AU (1) AU2018250217B2 (es)
BR (1) BR112019021021A2 (es)
CA (1) CA3059107A1 (es)
CL (1) CL2019002810A1 (es)
CO (1) CO2019011708A2 (es)
CR (1) CR20190503A (es)
CU (1) CU20190080A7 (es)
DK (1) DK3606519T3 (es)
DO (1) DOP2019000255A (es)
EA (1) EA201992299A1 (es)
EC (1) ECSP19078393A (es)
FI (1) FI3606519T3 (es)
IL (1) IL269711B (es)
JO (1) JOP20190221A1 (es)
MA (1) MA49047A (es)
MX (1) MX2019012013A (es)
NI (1) NI201900102A (es)
NZ (1) NZ758345A (es)
PE (1) PE20200009A1 (es)
PH (1) PH12019502288A1 (es)
PT (1) PT3606519T (es)
RU (1) RU2019134679A (es)
SG (1) SG11201909155VA (es)
TW (1) TWI779022B (es)
WO (1) WO2018187506A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787435B2 (en) * 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
MX2019013275A (es) 2017-05-12 2020-07-27 Enanta Pharm Inc Inhibidores de la quinasa 1 reguladora de la señal de apoptosis y métodos de uso de estos.
US11434249B1 (en) 2018-01-02 2022-09-06 Seal Rock Therapeutics, Inc. ASK1 inhibitor compounds and uses thereof
CN110407806B (zh) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
IL278368B2 (en) 2018-05-02 2024-06-01 Enanta Pharm Inc Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods for its use
WO2020006429A1 (en) * 2018-06-28 2020-01-02 Hepatikos Therapeutics, Llc Ask1 isoindolin-1-one inhibitors and methods of use thereof
US10968199B2 (en) 2018-08-22 2021-04-06 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020106707A1 (en) 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11466033B2 (en) 2019-03-25 2022-10-11 Enanta Pharmaceuticals, Inc. Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
CN112409332B (zh) * 2019-08-23 2023-12-08 广东东阳光药业股份有限公司 三氮唑衍生物及其在药物中的应用
JP2023514019A (ja) 2019-12-27 2023-04-05 ルピン・リミテッド 置換三環式化合物
KR20230003128A (ko) 2020-05-01 2023-01-05 화이자 인코포레이티드 Hpk1 억제제로서의 아잘락탐 화합물
WO2021224818A1 (en) * 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
WO2024020458A1 (en) * 2022-07-20 2024-01-25 Seal Rock Therapeutics, Inc. Method of treating organ diseases or disorders with ask1 inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
RS53176B (en) * 2010-02-03 2014-06-30 Takeda Pharmaceutical Company Limited KINASE INHIBITORS 1 REGULATING SIGNALS IN APOPTOSIS
WO2012079022A1 (en) * 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
JP5927201B2 (ja) 2010-12-16 2016-06-01 カルチャン リミテッド Ask1阻害ピロロピリミジン誘導体
EP3524243A1 (en) * 2014-09-24 2019-08-14 Gilead Sciences, Inc. Methods of treating liver disease
WO2017214359A1 (en) * 2016-06-10 2017-12-14 Venenum Biodesign Llc Novel clostridium difficile toxin inhibitors
US10787435B2 (en) * 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
SG11201906579UA (en) 2017-01-22 2019-08-27 Fujian Cosunter Pharmaceutical Co Ltd Pyridine derivative as ask1 inhibitor and preparation method and use thereof
EP3580224B1 (en) 2017-02-07 2022-07-13 Biogen MA Inc. Ask1 inhibiting agents
WO2018149284A1 (zh) 2017-02-16 2018-08-23 四川科伦博泰生物医药股份有限公司 激酶抑制剂及其制备方法和用途
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
WO2018157277A1 (en) 2017-02-28 2018-09-07 Eli Lilly And Company Isoquinolin and naphthydrin compounds
TW201833108A (zh) 2017-03-03 2018-09-16 大陸商江蘇豪森藥業集團有限公司 醯胺類衍生物抑制劑及其製備方法和應用
US11345676B2 (en) 2017-03-27 2022-05-31 Pharmakea, Inc. Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds
WO2019055540A1 (en) 2017-09-13 2019-03-21 D.E. Shaw Research, Llc COMPOUNDS AS INHIBITORS OF RAS AND THEIR USE
WO2020006429A1 (en) * 2018-06-28 2020-01-02 Hepatikos Therapeutics, Llc Ask1 isoindolin-1-one inhibitors and methods of use thereof

Also Published As

Publication number Publication date
NZ758345A (en) 2022-02-25
MX2019012013A (es) 2019-12-18
PH12019502288A1 (en) 2020-07-13
DOP2019000255A (es) 2019-12-15
SG11201909155VA (en) 2019-10-30
MA49047A (fr) 2020-02-12
PE20200009A1 (es) 2020-01-06
CU20190080A7 (es) 2020-10-20
RU2019134679A (ru) 2021-05-05
ECSP19078393A (es) 2019-12-27
CN110730661A (zh) 2020-01-24
BR112019021021A2 (pt) 2020-05-05
PT3606519T (pt) 2024-08-06
KR102665145B1 (ko) 2024-05-09
CO2019011708A2 (es) 2020-01-17
TW201838983A (zh) 2018-11-01
FI3606519T3 (fi) 2024-08-09
CN110730661B (zh) 2023-06-13
WO2018187506A1 (en) 2018-10-11
CR20190503A (es) 2020-02-28
DK3606519T3 (da) 2024-08-12
CA3059107A1 (en) 2018-10-11
AR111407A1 (es) 2019-07-10
US20210087167A1 (en) 2021-03-25
KR20190141166A (ko) 2019-12-23
EP3606519A1 (en) 2020-02-12
JP7196093B2 (ja) 2022-12-26
EA201992299A1 (ru) 2020-03-26
IL269711A (en) 2019-11-28
US20180291002A1 (en) 2018-10-11
TWI779022B (zh) 2022-10-01
AU2018250217B2 (en) 2022-05-19
IL269711B (en) 2021-12-01
JOP20190221A1 (ar) 2019-09-23
JP2020515589A (ja) 2020-05-28
AU2018250217A1 (en) 2019-11-07
EP3606519B1 (en) 2024-06-05
US10150755B2 (en) 2018-12-11
EP3606519A4 (en) 2020-12-02
CL2019002810A1 (es) 2020-03-27

Similar Documents

Publication Publication Date Title
ECSP19078393A (es) Compuestos inhibidores de ask1 y usos de los mismos
NI201900062A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2018002784A1 (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue.
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY36126A (es) ?compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr?.
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2020000747A1 (es) Formulaciones de niraparib.
CO2019009722A2 (es) Dendrímeros terapéuticos
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
UY36123A (es) Derivados de carboxamida
UY36124A (es) Derivados de carboxamida
MX2020004678A (es) Uso de profarmacos de riluzol para tratar ataxias.
CO2021008962A2 (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos
UY37872A (es) Derivados de difenilo y usos de los mismos
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos
AR111063A1 (es) Dendrímeros terapéuticos
CU20160170A7 (es) Derivados de carboxamida